PE20200839A1 - Anticuerpos anti-cd137 - Google Patents
Anticuerpos anti-cd137Info
- Publication number
- PE20200839A1 PE20200839A1 PE2020000155A PE2020000155A PE20200839A1 PE 20200839 A1 PE20200839 A1 PE 20200839A1 PE 2020000155 A PE2020000155 A PE 2020000155A PE 2020000155 A PE2020000155 A PE 2020000155A PE 20200839 A1 PE20200839 A1 PE 20200839A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L7/00—Arrangements for synchronising receiver with transmitter
- H04L7/04—Speed or phase control by synchronisation signals
- H04L7/10—Arrangements for initial synchronisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04B—TRANSMISSION
- H04B10/00—Transmission systems employing electromagnetic waves other than radio-waves, e.g. infrared, visible or ultraviolet light, or employing corpuscular radiation, e.g. quantum communication
- H04B10/25—Arrangements specific to fibre transmission
- H04B10/2575—Radio-over-fibre, e.g. radio frequency signal modulated onto an optical carrier
- H04B10/25752—Optical arrangements for wireless networks
- H04B10/25753—Distribution optical network, e.g. between a base station and a plurality of remote units
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Signal Processing (AREA)
- Computer Networks & Wireless Communication (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762539687P | 2017-08-01 | 2017-08-01 | |
| PCT/US2018/043632 WO2019027754A1 (en) | 2017-08-01 | 2018-07-25 | ANTI-CD137 ANTIBODIES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20200839A1 true PE20200839A1 (es) | 2020-08-13 |
Family
ID=63165504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020000155A PE20200839A1 (es) | 2017-08-01 | 2018-07-25 | Anticuerpos anti-cd137 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10906983B2 (enExample) |
| EP (2) | EP3661544B1 (enExample) |
| JP (2) | JP6743320B1 (enExample) |
| KR (2) | KR20210158420A (enExample) |
| CN (1) | CN111182919B (enExample) |
| AU (2) | AU2018311804B2 (enExample) |
| BR (1) | BR112020001441A2 (enExample) |
| CA (2) | CA3146758A1 (enExample) |
| CL (1) | CL2020000233A1 (enExample) |
| CO (1) | CO2020001050A2 (enExample) |
| CR (1) | CR20200042A (enExample) |
| DO (1) | DOP2020000020A (enExample) |
| EA (1) | EA202090204A1 (enExample) |
| EC (1) | ECSP20007663A (enExample) |
| ES (1) | ES2912651T3 (enExample) |
| IL (1) | IL272349B2 (enExample) |
| JO (1) | JOP20200016B1 (enExample) |
| MA (1) | MA49749A (enExample) |
| MX (1) | MX2020001351A (enExample) |
| PE (1) | PE20200839A1 (enExample) |
| PH (1) | PH12020500225A1 (enExample) |
| SA (1) | SA520411186B1 (enExample) |
| SG (1) | SG11202000747VA (enExample) |
| UA (1) | UA128388C2 (enExample) |
| WO (1) | WO2019027754A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201913147WA (en) | 2017-07-11 | 2020-02-27 | Compass Therapeutics Llc | Agonist antibodies that bind human cd137 and uses thereof |
| CR20200042A (es) * | 2017-08-01 | 2020-03-03 | Lilly Co Eli | Anticuerpos anti-cd137 |
| US11512134B2 (en) | 2017-08-01 | 2022-11-29 | Eli Lilly And Company | Anti-CD137 antibodies |
| US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
| EP3713961A2 (en) | 2017-11-20 | 2020-09-30 | Compass Therapeutics LLC | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| CN112020517B (zh) * | 2018-03-23 | 2024-10-29 | 伊莱利利公司 | 用于与抗pd-l1抗体组合的抗cd137抗体 |
| KR20240017090A (ko) * | 2018-03-23 | 2024-02-06 | 일라이 릴리 앤드 캄파니 | 항-pd-1 항체와의 조합을 위한 항-cd137 항체 |
| EP3823988A1 (en) * | 2018-07-19 | 2021-05-26 | Eli Lilly and Company | Bispecific antibodies targeting immune checkpoints |
| JP7598312B2 (ja) | 2018-07-23 | 2024-12-11 | ハイデルベルク ファーマ リサーチ ゲーエムベーハー | 同種異系の細胞療法における抗－ｃｄ１３７抗体薬物コンジュゲート（ａｄｃ）の使用 |
| MX2021001431A (es) | 2018-08-10 | 2021-05-12 | Chugai Pharmaceutical Co Ltd | Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso. |
| WO2020216947A1 (en) | 2019-04-24 | 2020-10-29 | Heidelberg Pharma Research Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| BR112021026309A2 (pt) | 2019-06-26 | 2022-06-07 | Ap Biosciences Inc | Anticorpos para ativação de células t |
| IL295382B1 (en) * | 2020-02-12 | 2026-08-01 | Chugai Seiyaku Kk | Anti-CD137 antigen-binding molecule for use in cancer treatment |
| WO2022111571A1 (zh) | 2020-11-25 | 2022-06-02 | 上海君赛生物科技有限公司 | 肿瘤浸润淋巴细胞培养基及其应用 |
| WO2024179465A1 (zh) | 2023-02-27 | 2024-09-06 | 上海君赛生物科技有限公司 | 表达膜结合细胞因子的肿瘤浸润淋巴细胞 |
| KR20250104655A (ko) | 2023-12-29 | 2025-07-08 | 쿠팡 주식회사 | 옵션 피커 화면 제공 방법 및 그 장치 |
| KR20250104669A (ko) | 2023-12-29 | 2025-07-08 | 쿠팡 주식회사 | 옵션 선택 가이드 정보 제공 방법 및 그 장치 |
| KR20250132789A (ko) | 2024-02-29 | 2025-09-05 | 쿠팡 주식회사 | 옵션 피커 화면 제공 방법 및 그 장치 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6362325B1 (en) | 1988-11-07 | 2002-03-26 | Advanced Research And Technology Institute, Inc. | Murine 4-1BB gene |
| US6303121B1 (en) | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
| US7211259B1 (en) | 1993-05-07 | 2007-05-01 | Immunex Corporation | 4-1BB polypeptides and DNA encoding 4-1BB polypeptides |
| IL129138A0 (en) | 1996-10-11 | 2000-02-17 | Bristol Myers Squibb Co | Methods and compositions for immunomodulation |
| AU2002364935A1 (en) | 2001-10-09 | 2003-06-23 | Mayo Foundation For Medical Education And Research | Enhancement of immune responses by 4-1bb-binding agents |
| US7288638B2 (en) * | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| WO2010042433A1 (en) | 2008-10-06 | 2010-04-15 | Bristol-Myers Squibb Company | Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases |
| NZ729044A (en) * | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| US10899840B2 (en) | 2014-02-04 | 2021-01-26 | Pfizer Inc. | Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer |
| EP3183269A2 (en) | 2014-08-22 | 2017-06-28 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
| TW201632559A (zh) * | 2015-02-22 | 2016-09-16 | 索倫多醫療公司 | 結合ｃｄ１３７之抗體治療劑 |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| GB201619648D0 (en) * | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel antibodies and uses thereof |
| CR20200042A (es) * | 2017-08-01 | 2020-03-03 | Lilly Co Eli | Anticuerpos anti-cd137 |
-
2018
- 2018-07-25 CR CR20200042A patent/CR20200042A/es unknown
- 2018-07-25 EA EA202090204A patent/EA202090204A1/ru unknown
- 2018-07-25 PE PE2020000155A patent/PE20200839A1/es unknown
- 2018-07-25 EP EP18752950.8A patent/EP3661544B1/en active Active
- 2018-07-25 ES ES18752950T patent/ES2912651T3/es active Active
- 2018-07-25 UA UAA202000367A patent/UA128388C2/uk unknown
- 2018-07-25 MX MX2020001351A patent/MX2020001351A/es unknown
- 2018-07-25 CN CN201880064332.2A patent/CN111182919B/zh active Active
- 2018-07-25 CA CA3146758A patent/CA3146758A1/en active Pending
- 2018-07-25 KR KR1020217041897A patent/KR20210158420A/ko not_active Ceased
- 2018-07-25 WO PCT/US2018/043632 patent/WO2019027754A1/en not_active Ceased
- 2018-07-25 KR KR1020207002814A patent/KR102344620B1/ko active Active
- 2018-07-25 MA MA049749A patent/MA49749A/fr unknown
- 2018-07-25 EP EP22159268.6A patent/EP4070811A1/en not_active Withdrawn
- 2018-07-25 CA CA3071383A patent/CA3071383C/en active Active
- 2018-07-25 US US16/497,493 patent/US10906983B2/en active Active
- 2018-07-25 JP JP2020505392A patent/JP6743320B1/ja active Active
- 2018-07-25 BR BR112020001441-9A patent/BR112020001441A2/pt active Search and Examination
- 2018-07-25 IL IL272349A patent/IL272349B2/en unknown
- 2018-07-25 SG SG11202000747VA patent/SG11202000747VA/en unknown
- 2018-07-25 AU AU2018311804A patent/AU2018311804B2/en active Active
-
2020
- 2020-01-28 JO JOP/2020/0016A patent/JOP20200016B1/ar active
- 2020-01-29 SA SA520411186A patent/SA520411186B1/ar unknown
- 2020-01-29 CO CONC2020/0001050A patent/CO2020001050A2/es unknown
- 2020-01-29 CL CL2020000233A patent/CL2020000233A1/es unknown
- 2020-01-30 PH PH12020500225A patent/PH12020500225A1/en unknown
- 2020-01-31 DO DO2020000020A patent/DOP2020000020A/es unknown
- 2020-01-31 EC ECSENADI20207663A patent/ECSP20007663A/es unknown
- 2020-07-29 JP JP2020128427A patent/JP7257364B2/ja active Active
-
2021
- 2021-12-02 AU AU2021277707A patent/AU2021277707A1/en not_active Abandoned
-
2022
- 2022-11-01 US US18/051,761 patent/US12453771B2/en active Active
-
2025
- 2025-09-30 US US19/346,308 patent/US20260109775A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
| PE20240802A1 (es) | Anticuerpos multiespecificos con especificidad para il-4r e il-31 | |
| PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| PE20090161A1 (es) | Anticuerpos monoclonales anti cxcl13 | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| AR112768A1 (es) | Anticuerpos anti-tigit | |
| PE20170916A1 (es) | Composiciones y metodos para anticuerpos dirigidos a bmp6 | |
| PE20240086A1 (es) | Anticuerpos anti-cd122 y usos de estos | |
| BR112015022978A2 (pt) | agente de ligação biespecífico, seu método de produção composição farmacêutica, proteína de fusão, uso, sequência de ácido nucleico, vetor, célula hospedeira, método de matar células tumorais e de inibir o crescimento tumoral | |
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| AR095432A1 (es) | Proteínas de unión a antígeno | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| PE20241349A1 (es) | Anticuerpos de union a cd3 | |
| PE20141162A1 (es) | Anticuerpos anti-il-23 | |
| EA035160B9 (ru) | Антитела к st2 и их применение | |
| NZ600512A (en) | Neutralizing prolactin receptor antibodies and their therapeutic use | |
| CO5601037A2 (es) | Anticuerpos anti-a beta y sus usos | |
| PE20130226A1 (es) | Anticuerpos hacia gdf8 humano | |
| PE20090688A1 (es) | MIEMBROS DE UNION PARA LAS MOLECULAS DE IgE | |
| AR104906A1 (es) | Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos | |
| PE20142170A1 (es) | Anticuerpos frente a los ligandos del receptor b1 de bradicinina |